119 related articles for article (PubMed ID: 2934581)
41. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
42. The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist.
Corson SL; Batzer FR; Gocial B; Maislin G
Fertil Steril; 1993 Jun; 59(6):1251-6. PubMed ID: 8495774
[TBL] [Abstract][Full Text] [Related]
43. [Peptid contraception--new principles for family planning].
Nillius SJ
Lakartidningen; 1981 Aug; 78(34):2845-8. PubMed ID: 7033692
[TBL] [Abstract][Full Text] [Related]
44. GnRH analogues for contraception.
Fraser HM
Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
[TBL] [Abstract][Full Text] [Related]
45. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
46. Failure of positive feedback of oestradiol during chronic intranasal luteinizing hormone-releasing hormone agonist treatment.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Feb; 16(2):147-51. PubMed ID: 6802530
[TBL] [Abstract][Full Text] [Related]
47. Gonadotropin releasing hormone agonists and the induction or augmentation of ovulation.
Martin MC
J Reprod Med; 1989 Dec; 34(12 Suppl):1034-8. PubMed ID: 2533619
[TBL] [Abstract][Full Text] [Related]
48. [Clinical study on LRH-A contraception by luteolysis].
Lu RK
Zhonghua Fu Chan Ke Za Zhi; 1989 Jan; 24(1):26-8, 58. PubMed ID: 2667912
[TBL] [Abstract][Full Text] [Related]
49. Gonadotrophin-releasing hormone agonists for new approaches to contraception in man.
Nillius SJ
Wien Klin Wochenschr; 1985 Dec; 97(23):865-73. PubMed ID: 3934848
[TBL] [Abstract][Full Text] [Related]
50. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial.
Henzl MR; Corson SL; Moghissi K; Buttram VC; Berqvist C; Jacobson J
N Engl J Med; 1988 Feb; 318(8):485-9. PubMed ID: 2963213
[TBL] [Abstract][Full Text] [Related]
51. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
[TBL] [Abstract][Full Text] [Related]
52. Interference in follicular maturation following acute intranasal LH-RH agonist administration during mid and late follicular phase.
Lemay A; Faure N
Int J Fertil; 1988; 33(1):60-7. PubMed ID: 2896176
[TBL] [Abstract][Full Text] [Related]
53. Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition.
Gudmundsson JA; Ljunghall S; Bergquist C; Wide L; Nillius SJ
J Clin Endocrinol Metab; 1987 Jul; 65(1):159-63. PubMed ID: 2953749
[TBL] [Abstract][Full Text] [Related]
54. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
Skarin G; Nillius SJ; Wide L
Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
[TBL] [Abstract][Full Text] [Related]
55. Intranasal LHRH agonist (Buserelin) after ovulation: a post-coital contraceptive approach.
Lemay A; Faure N; Labrie F; Fazekas AT
Contracept Deliv Syst; 1983 Apr; 4(2):107-25. PubMed ID: 12338631
[TBL] [Abstract][Full Text] [Related]
56. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues.
Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
J Assist Reprod Genet; 1998 Nov; 15(10):599-604. PubMed ID: 9866068
[TBL] [Abstract][Full Text] [Related]
57. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
Lemay A; Labrie F; Raynaud JP
Int J Fertil; 1980; 25(3):203-12. PubMed ID: 6108931
[TBL] [Abstract][Full Text] [Related]
58. Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized, intermittent regimen.
Werlin LB; Hodgen GD
J Clin Endocrinol Metab; 1983 Apr; 56(4):844-8. PubMed ID: 6403565
[TBL] [Abstract][Full Text] [Related]
59. Ovulation inhibition by administration of weekly gonadotropin-releasing hormone antagonist.
Kenigsberg D; Hodgen GD
J Clin Endocrinol Metab; 1986 Apr; 62(4):734-8. PubMed ID: 3081571
[TBL] [Abstract][Full Text] [Related]
60. Follicular stimulation versus ovulation induction in juvenile primates: importance of gonadotropin-releasing hormone dose.
Sopelak VM; Collins RL; Hodgen GD
J Clin Endocrinol Metab; 1986 Mar; 62(3):557-62. PubMed ID: 3080466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
